Form 4: Travere Therapeutics Officer Inrig Jula Reports Stock Transactions Following FDA Approval of FILSPARI

Following the FDA's full approval of FILSPARI, Travere Therapeutics' Chief Medical Officer, Jula Inrig, reports acquisition of shares through vested performance stock units and subsequent sale to cover tax obligations.

Summary

• On September 5, 2024, Jula Inrig, Chief Medical Officer of Travere Therapeutics, acquired 6,750 shares of common stock due to the vesting of performance restricted stock units (PSUs).
• The PSUs vested following the FDA's full approval of FILSPARI (sparsentan) in IgA Nephropathy.
• On September 9, 2024, Ms. Inrig sold 2,191 shares at $11.52 per share to cover tax withholding obligations related to the vested PSUs.
• These transactions changed Ms. Inrig's direct ownership of Travere Therapeutics common stock from 64,824 to 62,633 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the FDA approval of FILSPARI, which triggered the vesting of performance stock units. The subsequent sale of shares to cover taxes is a neutral event.

Positives

• The vesting of PSUs indicates the achievement of performance criteria, specifically the FDA's full approval of FILSPARI, which is a positive milestone for Travere Therapeutics.
• The sale of shares to cover tax obligations is a standard procedure and does not necessarily indicate a negative outlook on the company.

Industry Context

FDA approval of FILSPARI is a significant milestone in the treatment of IgA Nephropathy, placing Travere Therapeutics in a competitive position within the pharmaceutical industry.

Stakeholder Impact

• Shareholders may view the FDA approval of FILSPARI positively.
• Employees may be motivated by the achievement of performance goals linked to the FDA approval.

Key Dates